{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=8", "query": { "intervention": "Neoadjuvant therapy", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 2079, "total_pages": 208, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T22:56:54.648Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07586202", "title": "A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2026-07-28", "completion_date": "2028-04-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 4, "location_summary": "Duarte, California • Irvine, California • Portland, Oregon", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07586202" }, { "nct_id": "NCT06305767", "title": "A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Intismeran autogene", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Enfortumab Vedotin", "type": "BIOLOGICAL" }, { "name": "Surgery (RC plus PLND)", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2024-03-28", "completion_date": "2031-10-20", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 10, "location_summary": "Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06305767" }, { "nct_id": "NCT06854003", "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christine Ryan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-04-22", "completion_date": "2039-11-01", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06854003" }, { "nct_id": "NCT03609671", "title": "Emotions Immunology and Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer", "Emotions", "Immunology" ], "interventions": [ { "name": "Standard of Care + Experimental Individualized Therapy", "type": "BEHAVIORAL" }, { "name": "Control: Standard of Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Luz A. Venta, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2015-11-23", "completion_date": "2019-03-18", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03609671" }, { "nct_id": "NCT03794544", "title": "Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable", "Early-stage", "NSCLC" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Oleclumab", "type": "COMBINATION_PRODUCT" }, { "name": "Monalizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Danvatirsen", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "102 Years", "sex": "ALL", "summary": "18 Years to 102 Years" }, "enrollment_count": 84, "start_date": "2019-03-08", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2022-02-24", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 10, "location_summary": "La Jolla, California • Fort Myers, Florida • Leesburg, Florida + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Leesburg", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03794544" }, { "nct_id": "NCT01798004", "title": "Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ganglioneuroblastoma", "Stage 1 Neuroblastoma", "Stage 2 Neuroblastoma", "Stage 2A Neuroblastoma", "Stage 2B Neuroblastoma", "Stage 3 Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 150, "start_date": "2013-04-09", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 113, "location_summary": "Birmingham, Alabama • Downey, California • Duarte, California + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798004" }, { "nct_id": "NCT00731952", "title": "Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Velcade and Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2006-06", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2017-05-04", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00731952" }, { "nct_id": "NCT04493164", "title": "CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Gene Mutations", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-12-30", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493164" }, { "nct_id": "NCT07047807", "title": "PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "PDAC - Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "PDAC-PATHWAYS", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-10-06", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07047807" }, { "nct_id": "NCT01394211", "title": "Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2011-07-13", "completion_date": "2012-04-12", "has_results": true, "last_update_posted_date": "2018-07-26", "last_synced_at": "2026-10-30T22:56:54.648Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01394211" } ] }